Patents by Inventor Julie Bird

Julie Bird has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • scFv-Fc dimers that bind transforming growth factor-?1 with high affinity, avidity and specificity
    Patent number: 11976112
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: May 7, 2024
    Assignee: Genzyme Coporation
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
    Publication number: 20240117028
    Abstract: A modified IgG antibody binds and neutralizes TGF?l selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 11, 2024
    Applicant: Genzyme Corporation
    Inventors: Huawei QIU, Julie BIRD
  • Modified-IgG antibodies that bind transforming growth factor-BETA1 with high affinity, avidity and specificity
    Patent number: 11834495
    Abstract: A modified IgG antibody binds and neutralizes TGF?1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: December 5, 2023
    Assignee: Genzyme Corporation
    Inventors: Huawei Qiu, Julie Bird
  • SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
    Publication number: 20220363740
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Application
    Filed: April 4, 2022
    Publication date: November 17, 2022
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
    Publication number: 20220315649
    Abstract: A modified IgG antibody binds and neutralizes TGF?1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 6, 2022
    Applicant: Genzyme Corporation
    Inventors: Huawei Qiu, Julie Bird
  • scFv-Fc dimers that bind transforming growth factor-?1 with high affinity, avidity and specificity
    Patent number: 11325971
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: May 10, 2022
    Assignee: Genzyme Corporation
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • Modified-IgG antibodies that bind transforming growth factor-?1 with high affinity, avidity and specificity
    Patent number: 11325970
    Abstract: A modified IgG antibody binds and neutralizes TGF?1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 10, 2022
    Assignee: Genzyme Corporation
    Inventors: Huawei Qiu, Julie Bird
  • SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
    Publication number: 20200131258
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 30, 2020
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • ScFv-Fc dimers that bind transforming growth factor-BETA1 with high affinity, avidity and specificity
    Patent number: 10508146
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: December 17, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
    Publication number: 20180222970
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Application
    Filed: March 3, 2016
    Publication date: August 9, 2018
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
    Publication number: 20180044412
    Abstract: A modified IgG antibody binds and neutralizes TGF?1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 15, 2018
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Julie Bird